Strides Pharma Q1 FY27 Results: Revenue Grows 13%, Reported PAT Surges 57%

What Happened ?

Strides Pharma delivered a steady start to FY27 with revenue rising 13% year-on-year, driven by strong growth across Ex-US markets while maintaining stable performance in the U.S. business.

Although higher freight and operating expenses related to ongoing geopolitical disruptions affected margins, the company reported improved profitability through disciplined execution and operational efficiency.

Reported earnings also benefited from the sale of a majority stake in Pivot Path, the company’s captive Global Capability Centre (GCC). 

key details

Business & Operational Highlights:

• Revenue increased 13% YoY to ₹1,265.4 crore.
• Ex-US Markets grew 17% YoY to ₹587.5 crore, driven by broad-based market performance.
• US business remained stable, growing 4% YoY to ₹628.2 crore.
• Gross profit increased 14% YoY, with gross margin improving to 60.9%.
• EBITDA rose 5.4% YoY to ₹229.8 crore despite approximately ₹13.1 crore of additional freight and operating costs caused by geopolitical disruptions.
• Operational PAT increased 8% YoY to ₹123.1 crore.
• Reported PAT rose 56.7% YoY to ₹165.5 crore following the gain from the divestment of the majority stake in Pivot Path.
• The company unlocked ₹100 crore of value through the Pivot Path transaction while retaining meaningful participation in its future growth. 

Note:

• During the quarter, Strides reduced net debt by ₹11.9 crore, maintained a Net Debt-to-EBITDA ratio of 1.52x, and improved its EcoVadis sustainability score to 68/100, representing a 19-point improvement over the previous year. 

Risk Analysis

Summary:

• Strides reported healthy revenue growth despite cost pressures. However, geopolitical disruptions continue to increase freight and operating expenses, which may affect margins if sustained.

Key Risks:

• Elevated freight and logistics costs due to geopolitical developments.
• EBITDA margin declined despite higher revenue growth.
• Continued investments in working capital may affect cash flows.
• Growth in regulated markets remains subject to pricing and regulatory dynamics.

Worst Case:

• If geopolitical disruptions persist or freight costs remain elevated, profitability could remain under pressure despite continued revenue growth.

Risk Level: Medium

Company Commentary

Management highlighted the following during the quarter:

• Managing Director & Group CEO Badree Komandur said the company delivered a steady start to FY27 with strong contributions from Ex-US markets.
• Management highlighted that investments made over the past few years are now driving diversified growth across international markets.
• The company remains focused on mitigating freight and operating cost pressures through continuous cost optimization.
• Strides also emphasized balance sheet improvement through lower net debt and continued focus on sustainable, profitable growth.